Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Five Of The International Chefs Taking Part In Good/goût De France - Yahoo News

Here is a closer look at five of the chefs representing the event in five gourmet hotspots. > Neil Perry, Sydney, Australia One of the most influential chefs in Australia, Neil Perry has established something of a culinary empire, with several restaurants located between Sydney, Melbourne and Perth. At the center of this empire is his Sydney restaurant Rockpool, which spotlights the port city's fresh seafood and has earned praise from some of the world's most influential guidebooks. Perry also designs the business and first class menus for Qantas Airways, Australia's national carrier.
For the original version including any supplementary images or video, visit natural gout cures href='http://news.yahoo.com/five-international-chefs-taking-part-good-t-france-165550383.html' >http://news.yahoo.com/five-international-chefs-taking-part-good-t-france-165550383.html

Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease - Yahoo Finance

Arhalofenate works by lowering the levels of uric acid and reducing the inflammation. "Results from our clinical program to date suggest that arhalofenate may represent a new paradigm for the treatment of gout," Pol Boudes, CymaBay's chief medical officer, said. This is the first study to show that arhalofenate produces reductions in flares without concomitant dosing of colchicine, the company said. Colchicine is an anti-inflammatory compound that is commonly prescribed to treat gout. The compound has been available in the United States for more than half a century in injectable form.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cymabays-gout-drug-meets-main-121904951.html

CymaBay's gout drug meets main goal in mid-stage study - Yahoo Finance

Revive is currently evaluating Bucillamine in a Phase II-A clinical study in the U.S. for the treatment of gout.For cystinuria, Bucillamine has shown the potential to be an effective agent in both non-clinical and clinical studies in the treatment of cystinuria and may be a new therapeutic agent for cystinuria in place of monothiol compounds such as tiopronin (Thiola) and D-penicillamine which currently treat cystinuria(Source: T. Yoshioka et al, A new therapeutic agent for cystinuria, Urolithiasis 2: 571-574, (1994)).For Wilson disease, Bucillamine has shown in non-clinical studies the potential to be an effective chelating agent in comparison to other chelating agents that treat Wilson disease such as D-penicillamine (Source: Y. Tagawa et al, Protective effects of chelating agents against renal toxicity of gold sodium thiomalate in rats, Arch Toxicol (1991) 65:532-536). About Cystinuria Cystinuria is a rare autosomic recessive genetic disorder that causes high levels of cysteine in the urine thus causing kidney stones to form. This can lead to significant morbidity in affected patients due to the often large and recurrent resulting kidney stones.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/revive-therapeutics-expands-orphan-drug-133300813.html

CymaBay to Present at Upcoming Investor Conferences - Yahoo Finance

Without proper care, chronic conditions can also contribute to a seniors re-admission to a hospital. I have listed for you some common senior conditions that contribute to hospitalization and readmissions. While a number of factors can contribute to a senior's re-admission to a hospital after being transitioned home, there are six common conditions that are the most prevalent causes: arthritis; congestive heart failure; diabetes; myocardial infarction (heart attack); pneumonia; and comorbidity. Arthritis Arthritis is a chronic disease, which is characterized by more than 100 conditions that primarily affect a bodys joints. Some of the most common forms are osteoarthritis, rheumatoid arthritis, fibromyalgia and gout. The chances of getting arthritis, especially osteoarthritis, which is caused by the deterioration of a joints cartilage, increases with age, making it likely a senior may suffer from the diseases effects. Some with osteoarthritis have knee or hip replacement surgery to help relieve the pain in their joints. Others use medication and lifestyle changes such as exercise and a proper diet to ease their symptoms.
For the original version including any supplementary images or video, visit http://www.thecommunityvoice.com/article.php?id=9645

The Community Voice - Chronic symptoms a warning sign for hospitalization risk

Cowen and Company 35th Annual Health Care Conference Boston Marriott Copley Place Hotel, Boston, MA Wednesday, March 4 The Ritz-Carlton, Laguna Niguel, CA Tuesday, March 10 BioCentury 22ndAnnual Future Leaders In The Biotech Industry Millennium Broadway Hotel & Conference Center, New York, NY Friday, March 20 9:00 - 9:25 a.m. EST The Cowen and Company and ROTH presentations will be webcast live and available for replay for up to 30 days at http://ir.cymabay.com/events . About CymaBay CymaBay Therapeutics, Inc. ( CBAY ) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in gout and diet multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cymabay-present-upcoming-investor-conferences-130000542.html

Don't be the product, buy the product!